Astrazeneca plc
NASDAQ: AZN
$67.01
+$0.43 (+0.6%)
Closing Price on January 10, 2025
AZN Articles
It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1 billion to fail to get the drug to market. Like the movie business, a drug company tries to develop that...
Published:
Equities started the day with a solid move up, but lost momentum after about half an hour. The downward move lasted into the late morning, at which time stocks started a fitful climb back up. There...
Published:
Last Updated:
These are some of Tuesday’s top analyst upgrades, downgrades, and initiations seen from Wall Street research calls. Aixtron SE (NASDAQ: AIXG) Raised to Equalweight at Morgan Stanley. Alcatel-Lucent...
Published:
Sales for the big pharmaceutical companies are expected to be hit by pricing pressure in Europe, a lack of urgent new on the coming flu season, lower rates of prescription writing, and more...
Published:
Last Updated:
Once patent protection expires on a prescription drug, the drug’s maker can take a serious beating in revenue and profitability. One way to make up for the loss is to get US Food & Drug...
Published:
These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Friday morning. Advanced Micro Devices, Inc. (NYSE: AMD) Raised to Market Perform at...
Published:
Last Updated:
We may have just witnessed an oversold bounce in the stock market, or we may be in for more days of recovery. The markets are flirting with six weeks of negative performance and one day is not...
Published:
Last Updated:
The drug sector has become rather boring and investors already know all about the ongoing patent expiration threats that loom in the industry. The good news is that the drug sector does still offer...
Published:
Last Updated:
American Depository Receipts, or ADRs, are generally called American Depository Shares, or ADSs, now. We found after some routine screens that there were many 3%, 4%, and 5% or higher dividend...
Published:
Last Updated:
These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Wednesday morning. AstraZeneca plc (NYSE: AZN) Cut to Neutral at UBS. CenterPoint...
Published:
Last Updated:
The method of using capital from the corporate treasury to return capital to shareholders via share repurchase programs has long been under question. Most buybacks never are fully utilized, and...
Published:
Last Updated:
These are some of this Tuesday’s key analyst upgrades, downgrades, and initiations seen in Wall Street research calls. Amgen Inc. (NASDAQ: AMGN) Started as Neutral at Credit Suisse. AstraZeneca...
Published:
Last Updated:
These are some of this Wednesday’s top analyst upgrades, downgrades, and initiations seen in Wall Street research notes: Applied Materials Inc. (NASDAQ: AMAT) Started as Neutral at Susquehanna....
Published:
Last Updated:
There are many research calls this Thursday morning and these are just some of the top analyst upgrades, downgrades, and initiations seen in Wall Street research notes: Altria Group Inc. (NYSE: MO)...
Published:
Last Updated:
These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research early this Wednesday. Some of the U.S. calls will get pretty thin as we get closer to July 4...
Published:
Last Updated:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.